BiotechTube
Home/Pipeline/Heparin-based candidate for Oncology

Heparin-based candidate for Oncology

Cancer

Pre-clinicalActive

Key Facts

Indication
Cancer
Phase
Pre-clinical
Status
Active
Company
Intellihep

About Intellihep

IntelliHep is a private, pre-clinical stage biotech exploiting a proprietary platform to engineer novel heparin-based compounds. Its core focus is on in-house development of lead candidates for Alzheimer's disease and cancer, with broader potential applications in inflammation, angiogenesis, and regenerative medicine. Founded in 2019 and based in London, the company is currently pre-revenue and built on a team with deep expertise in heparin glycobiology and chemistry.

View full company profile

Therapeutic Areas

NeurodegenerationOncologyInflammationRegenerative Medicine

Other Cancer Drugs

DrugCompanyPhase
Not Specified (Oncology Focus)Narwhal BioPre-clinical
EDM Platform for Genetic MedicineCoastar TherapeuticsPre-clinical
CO-1Caedo OncologyPre-clinical
Anti-CD99 monoclonal antibodyCaedo OncologyDiscovery/Pre-clinical
Anti-HLA class I monoclonal antibodyCaedo OncologyDiscovery/Pre-clinical
Triapine®NanopharmaceuticsClinical
Ammonium TetrathiomolybdateNanopharmaceuticsClinical
Aza-TdCNanopharmaceuticsClinical
Undisclosed Oncology Program(s)Cell BioEnginesPhase 1
No-alpha IL-2 MuteinSarcoMed USAPre-clinical
PMIS TherapeuticNaturemiRIPreclinical/Clinical (unspecified)
AUM302 (formerly IBL-302)Inflection BiosciencesPre-clinical (partnered)